Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman | 75k | -- | 1974 |
Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 1.08M | 457.97k | 1979 |
Mr. Bruce N. Jacobs CFA | Chief Financial Officer | 671.2k | 249.77k | -- |
Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer | 614.5k | -- | 1963 |
Ms. Ellen V. Chiniara Esq., J.D. | Chief Legal Officer & Corporate Secretary | 640.35k | -- | 1959 |
Dr. Jared A. Gollob M.D. | Chief Medical Officer | 723.6k | -- | 1965 |
Ms. Karen Weisbach | Head of People & Culture | -- | -- | -- |
Dr. Juliet Williams B.A Ph.D. | Head of Research | -- | -- | -- |
Kymera Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 184
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
February 20, 2025 at 1:30 PM UTC - February 24, 2025 at 1:30 PM UTC
Kymera Therapeutics, Inc. Earnings Date